Publication:
Apomorphine in the treatment of parkinson's disease

dc.contributor.authorOzkan, Serhat
dc.contributor.authorElibol, Bulent
dc.contributor.authorOzkaynak, Sehur Sibel
dc.contributor.authorCakmur, Raif
dc.contributor.authorAkbostanci, Muhittin Cenk
dc.contributor.authorHanagasi, Hasmet
dc.contributor.authorDogu, Okan
dc.contributor.buuauthorErer, Sevda
dc.contributor.buuauthorERER ÖZBEK, ÇİĞDEM SEVDA
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.
dc.contributor.orcid0000-0002-2274-3230
dc.contributor.researcheridG-9559-2014
dc.date.accessioned2024-06-26T11:30:37Z
dc.date.available2024-06-26T11:30:37Z
dc.date.issued2021-12-01
dc.description.abstractApomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson's disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a "treatment management guideline," which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature.
dc.identifier.doi10.4274/tnd.2021.06706
dc.identifier.endpage365
dc.identifier.issn1301-062X
dc.identifier.issue4
dc.identifier.startpage358
dc.identifier.urihttps://doi.org/10.4274/tnd.2021.06706
dc.identifier.urihttps://hdl.handle.net/11452/42439
dc.identifier.volume27
dc.identifier.wos000740715600001
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherTürk Nöroloji Derneği
dc.relation.journalTurkish Journal Of Neurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTerm follow-up
dc.subjectSubcutaneous apomorphine
dc.subjectDouble-blind
dc.subjectUltrasound treatment
dc.subjectInfusion
dc.subjectMotor
dc.subjectEfficacy
dc.subjectReceptor
dc.subjectApomorphine
dc.subjectParkinson's disease
dc.subjectTreatment
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectClinical neurology
dc.subjectNeurosciences & neurology
dc.titleApomorphine in the treatment of parkinson's disease
dc.typeReview
dspace.entity.typePublication
relation.isAuthorOfPublicationfb9c4353-c7bb-4165-951e-f6153aadc524
relation.isAuthorOfPublication.latestForDiscoveryfb9c4353-c7bb-4165-951e-f6153aadc524

Files

Collections